National Pension Service Raises Stake in Moderna, Inc. (NASDAQ:MRNA)

National Pension Service raised its stake in Moderna, Inc. (NASDAQ:MRNA) by 10.3% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 813,893 shares of the company’s stock after acquiring an additional 75,817 shares during the period. National Pension Service’s holdings in Moderna were worth $54,392,000 at the end of the most recent quarter.

Other hedge funds have also recently modified their holdings of the company. Van ECK Associates Corp raised its holdings in shares of Moderna by 75.4% during the third quarter. Van ECK Associates Corp now owns 266,929 shares of the company’s stock valued at $17,839,000 after acquiring an additional 114,769 shares in the last quarter. Janney Montgomery Scott LLC boosted its stake in shares of Moderna by 6.3% during the 3rd quarter. Janney Montgomery Scott LLC now owns 12,767 shares of the company’s stock valued at $853,000 after purchasing an additional 756 shares in the last quarter. Stephens Inc. AR increased its position in shares of Moderna by 7.9% during the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after buying an additional 245 shares during the period. AustralianSuper Pty Ltd raised its stake in Moderna by 27.0% in the third quarter. AustralianSuper Pty Ltd now owns 14,507 shares of the company’s stock worth $970,000 after buying an additional 3,084 shares in the last quarter. Finally, Meitav Investment House Ltd. lifted its holdings in Moderna by 96.6% in the third quarter. Meitav Investment House Ltd. now owns 226,903 shares of the company’s stock worth $15,164,000 after buying an additional 111,475 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Insider Buying and Selling

In other news, CFO James M. Mock sold 715 shares of the firm’s stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now directly owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. In other Moderna news, CFO James M. Mock sold 1,321 shares of the stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $79.39, for a total transaction of $104,874.19. Following the sale, the chief financial officer now directly owns 8,600 shares in the company, valued at $682,754. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the sale, the chief financial officer now owns 9,505 shares of the company’s stock, valued at approximately $571,440.60. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 3,184 shares of company stock valued at $238,531 over the last ninety days. Company insiders own 15.20% of the company’s stock.

Moderna Stock Down 0.5 %

NASDAQ:MRNA opened at $53.29 on Wednesday. Moderna, Inc. has a fifty-two week low of $52.08 and a fifty-two week high of $170.47. The company’s 50-day simple moving average is $63.53 and its 200-day simple moving average is $100.31. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. The stock has a market capitalization of $20.48 billion, a P/E ratio of -3.46 and a beta of 1.69.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. TD Cowen lowered their target price on Moderna from $70.00 to $60.00 and set a “hold” rating for the company in a research note on Friday, September 13th. The Goldman Sachs Group reduced their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research report on Monday, September 16th. Hsbc Global Res raised shares of Moderna from a “moderate sell” rating to a “hold” rating in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft raised shares of Moderna from a “sell” rating to a “hold” rating and decreased their target price for the company from $85.00 to $80.00 in a research note on Wednesday, August 7th. Finally, JPMorgan Chase & Co. cut their price target on Moderna from $70.00 to $59.00 and set an “underweight” rating on the stock in a research note on Monday. Two investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat.com, Moderna has a consensus rating of “Hold” and an average price target of $94.00.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.